NCT00822341View on ClinicalTrials.gov

Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Healthy
Interventions
DRUG

TG-0054

0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion

Trial Locations (1)

21225

PAREXEL Clinical Pharmacology Research Unit Harbor Hospital Center, Baltimore

Sponsors
All Listed Sponsors
lead

GPCR Therapeutics, Inc.

INDUSTRY